Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Bristol Myers Squibb (NYSE: BMY) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the ...

Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer ...

An attorney for Bristol Myers Squibb on Friday urged a New York federal judge to dismiss a $6.4 billion action against the pharmaceutical giant, claiming the plaintiff has no subject matter ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Bristol Myers Squibb's rally from the July 2024 bottom is well deserved as the market rotated from high growth to high dividend-yielding sectors. Learn more on BMY stock here.

Discover Bristol-Myers Squibb's groundbreaking patent for personalized SLE treatment, utilizing IKZF3 gene expression to optimize dosage for better patient outcomes.

An array of clinical trial results and regulatory decisions helped boost shares of Gilead Sciences, Bristol-Myers Squibb, and Vertex Pharmaceuticals. The pharma industry has underperformed in 2024 ...

Bristol Myers Squibb (NYSE ... Disappointing results from the pharmaceutical giant have pressured the stock in recent years; it's currently down about 34% from its record high in 2022.